Immunological Studies in Ugandan Patients with Hepatocellular Carcinoma

Overview

Journal Br Med J

Specialty General Medicine

Date 1973 Jan 6

PMID 4345903

Citations 5

Authors

A Primack

C L Vogel

L F Barker

Affiliations

Soon will be listed here.

Abstract

Immunological studies were performed on Ugandan patients with hepatocellular carcinoma to test the hypothesis that the high rate of persistence of hepatitis-associated antigen in these patients is the result of defects in host immune response. The responses to 1-chloro-2,4-dinitrobenzene sensitization and to a battery of recall skin test antigens were normal, as was the humoral antibody response to tularaemia antigen. Neither hypogammaglobulinaemia nor specific immunoglobulin deficiencies were found. Thus it appears unlikely that generalized defects in host immune responses can account for the high incidence of persistent hepatitis B virus infection found in Ugandan patients with hepatocellular carcinoma.

Citing Articles

Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.

Rai V, Abdo J, Alsuwaidan A, Agrawal S, Sharma P, Agrawal D Mol Cell Biochem. 2017; 437(1-2):13-36.

PMID: 28593566 DOI: 10.1007/s11010-017-3092-z.

Primary liver cancer and its relationship to chronic infection with the hepatitis B virus.

Hadziyannis S Springer Semin Immunopathol. 1981; 3(4):473-85.

PMID: 6267725 DOI: 10.1007/BF01951494.

Serum immunoglobulin levels in primary liver cancer: relationship to underlying cirrhosis and hepatitis-B (surface) antigenaemia.

Ipp T, MACNAB G, Geddes E, Kew M Br J Cancer. 1975; 32(4):509-11.

PMID: 174706 PMC: 2024768. DOI: 10.1038/bjc.1975.253.

Tropical cirrhosis and hepatoma.

Coady A J R Coll Physicians Lond. 1976; 10(2):133-44.

PMID: 173844 PMC: 5366416.

Hepatitis-B surface antigen and antibody in Bantu patients with primary hepatocellular cancer.

MACNAB G, Urbanowicz J, Geddes E, Kew M Br J Cancer. 1976; 33(5):544-8.

PMID: 58663 PMC: 2024954. DOI: 10.1038/bjc.1976.86.

References

Smith J, Blumberg B . Viral hepatitis, postnecrotic cirrhosis, and hepatocellular carcinoma. Lancet. 1969; 2(7627):953. DOI: 10.1016/s0140-6736(69)90604-7. View

Blumberg B, Friedlaender J, Woodside A, Sutnick A, London W . Hepatitis and Australia antigen: autosomal recessive inheritance of susceptibility to infection in humans. Proc Natl Acad Sci U S A. 1969; 62(4):1108-15. PMC: 223621. DOI: 10.1073/pnas.62.4.1108. View

Ziegler J, Lewis M, Luyombya J, Kiryabwire J . Immunologic studies in patients with malignant melanoma in Uganda. Br J Cancer. 1969; 23(4):729-34. PMC: 2008492. DOI: 10.1038/bjc.1969.89. View

Gocke D, Howe C . Rapid detection of Australia antigen by counterimmunoelectrophoresis. J Immunol. 1970; 104(4):1031-4. View

Sherlock S, Fox R, Niazi S, Scheuer P . Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. Lancet. 1970; 1(7659):1243-7. DOI: 10.1016/s0140-6736(70)91737-x. View

Hadziyannis S, Merikas G, Afroudakis A . Hepatitis-associated antigen in chronic liver disease. Lancet. 1970; 1(7663):100. DOI: 10.1016/s0140-6736(70)92672-3. View

Vogel C, ANTHONY P, Mody N, Barker L . Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma. Lancet. 1970; 2(7674):621-4. DOI: 10.1016/s0140-6736(70)91396-6. View

Prince A, Leblanc L, Krohn K, MASSEYEFF R, ALPERT M . S.H. antigen and chronic liver disease. Lancet. 1970; 2(7675):717-8. DOI: 10.1016/s0140-6736(70)91981-1. View

Denison E, Peters R, Reynolds T . Familial hepatoma with hepatitis-associated antigen. Ann Intern Med. 1971; 74(3):391-4. DOI: 10.7326/0003-4819-74-3-391. View

10.

Teres J, Guardia J, Bruguera M, Rodes J . Hepatitis-associated antigen and hepatocellular carcinoma. Lancet. 1971; 2(7717):215. DOI: 10.1016/s0140-6736(71)90926-3. View

11.

Alpert E, Isselbacher K . Hepatitis-associated antigen and hepatoma in the U.S. Lancet. 1971; 2(7733):1087. DOI: 10.1016/s0140-6736(71)90399-0. View

12.

Tong M, Sun S, Schaeffer B, Chang N, Lo K, Peters R . Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med. 1971; 75(5):687-91. DOI: 10.7326/0003-4819-75-5-687. View

13.

Anand S, Malaviya A . H.A.A. in primary liver-cell carcinoma. Lancet. 1971; 2(7732):1032-3. DOI: 10.1016/s0140-6736(71)90345-x. View

14.

Bluming A, Vogel C, Ziegler J, Mody N, Kamya G . Immunological effects of BCG in malignant melanoma: two modes of administration compared. Ann Intern Med. 1972; 76(3):405-11. DOI: 10.7326/0003-4819-76-3-405. View

15.

Vogel C, ANTHONY P, Sadikali F, Barker L, Peterson M . Hepatitis-associated antigen and antibody in hepatocellular carcinoma: results of a continuing study. J Natl Cancer Inst. 1972; 48(6):1583-8. View

16.

Grabar P . The use of immunochemical methods in studies on proteins. Adv Protein Chem. 1958; 13:1-33. DOI: 10.1016/s0065-3233(08)60597-5. View

17.

Sutnick A, London W, Blumberg B, Yankee R, Gerstley B, Millman I . Australia antigen (a hepatitis-associated antigen) in leukemia. J Natl Cancer Inst. 1970; 44(6):1241-9. View

18.

Waldorf D, Sheagren J, TRAUTMAN J, Block J . Impaired delayed hypersensitivity in patients with lepromatous leprosy. Lancet. 1966; 2(7467):773-6. DOI: 10.1016/s0140-6736(66)90366-7. View

19.

Okochi K, Murakami S . Observations on Australia antigen in Japanese. Vox Sang. 1968; 15(5):374-85. DOI: 10.1111/j.1423-0410.1968.tb04078.x. View

20.

Amos B, Yunis E . Human leukocyte antigenic specificity HL-A3: frequency of occurrence. Science. 1969; 165(3890):300-2. DOI: 10.1126/science.165.3890.300. View